Risk of severe COVID in solid organ transplant recipient.


Journal

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
ISSN: 1988-9518
Titre abrégé: Rev Esp Quimioter
Pays: Spain
ID NLM: 9108821

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 27 11 2023
pubmed: 24 11 2023
entrez: 24 11 2023
Statut: ppublish

Résumé

Despite the fact that COVID is today not a life-threat for the general population, recipients of solid organ transplantation should be viewed as a high risk group for severe COVID. Repetitive doses of SARS-CoV-2 vaccine still fail to protect SOT recipients from infection, disease or even death caused by COVID. A more frequent need for medical care may initially place these patients at greater chances of SARS-CoV-2 infection. Immunosuppression after engrafting and underlying medical conditions that led to the practice of SOT contribute to more risk of severe infection. Immunosuppression also blunts the intensity of humoral and cellular responses after vaccination, even when several booster doses have been administered. Still, vaccination is the best strategy to prevent a fatal outcome in case of SARS-CoV-2 infection, with a particular reduction in mortality. SOT recipients should be considered a high-risk population that need yearly SARS-CoV-2 vaccination.

Identifiants

pubmed: 37997864
doi: 10.37201/req/s01.04.2023
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-17

Informations de copyright

©The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

Auteurs

P Barreiro (P)

Pablo Barreiro MD PhD, Regional Public Health Laboratory. Comunidad de Madrid. Infectious Diseases. Internal Medicine. Hospital General Universitario La Paz. Madrid, Spain. Department of Medical Specialties and Public Health. School of Medicine. Universidad Rey Juan Carlos, 28922 Madrid, Spain. pablo.barreiro@salud.madrid.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH